Bipolar I
Resources for Patients and Caregivers
Bipolar I Disorder— defined by manic episodes that last at least 7 days, or by manic symptoms that are so severe that the person needs immediate hospital care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks.
Cluster Number:
Wiki Number: 08-Bipolar I
Diagnosis: This requires just one full manic episode where the individual may be “high” for several days.
US Patients: 1% of the US population in their lifetimes.
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: Typically it will be followed by one or more depressive stretches of time.
Progression: Relatively good, may last 6 months or 25% go to PTSD or Major Depressive Disorder
Causes:
Medications:Can be reduced by other prescribed drugs.
Therapies:
Youtube Video: Faces of Bipolar Disorder (PART 2) “Bipolar Type 1”
Amazon or Library Book: Bipolar Disorder 1
How to Survive and Thrive
Click the book to link or order from Amazon.
Support Group: dsballiance.org; 800-326-3632
(Depression and Bipolar Support Alliance)
Contact your local Social Security offic for possible Disability Benefits through their Disability Determination Services,
Section 12.04.
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- One-Shot Remote Integration of Macromolecular Synaptic Elements on a Chip for Ultrathin Flexible Neural Network Systemby Jiyun Lee on May 19, 2024
The field of biomimetic electronics that mimic synaptic functions has expanded significantly to overcome the limitations of the von Neumann bottleneck. However, the scaling down of the technology has led to an increasingly intricate manufacturing process. To address the issue, we present a one-shot integrable electropolymerization (OSIEP) method with remote controllability for the deposition of synaptic elements on a chip by exploiting bipolar electrochemistry. Condensing synthesis, deposition,...
- Evidence for Therapeutic Drug Monitoring of Atypical Antipsychoticsby Veronika Krejčí on May 18, 2024
Second-generation antipsychotics (SGAs), also known as atypical antipsychotics, are a newer class of antipsychotic drugs used to treat schizophrenia, bipolar disorder, and related psychiatric conditions. The plasma concentration of antipsychotic drugs is a valid measure of the drug at its primary target structure in the brain, and therefore determines the efficacy and safety of these drugs. However, despite the well-known high variability in pharmacokinetics of these substances, psychiatric...
- The role of metabolic syndrome as a mediator in the relationship between CCL11 levels and the presence of a mood episode with mixed features in young adults with bipolar disorderby Letícia Vasques Bender on May 18, 2024
Mixed features presentation in bipolar disorder (BD) represents the most severe form of the disease. BD may lead to cognitive and functional deterioration, a process known as neuroprogression, which appears to be exacerbated by increased serum levels of CCL11, a neuroprogression-related cytokine. Metabolic syndrome (MetS) is highly prevalent in BD, and it is known that the presence of MetS may increase inflammation, which may contribute to increased CCL11 levels, and consequently impact on the...
- Editorial: Combining Genetic and Clinical Predictors of Bipolar Disorder: Towards Improving the Diagnostic Precision in Youthby En-Nien Tu on May 18, 2024
No abstract